EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor

ACS Chemical Biology

Volumn 11, Issue 9, 2016, Pages 2499-2505

  De Mol, Eva ^a   Fenwick, R Bryn ^a   Phang, Christopher T W ^a   Buzón, Victor ^b   Szulc, Elzbieta ^a   De La Fuente, Alex ^a   Escobedo, Albert ^a   García, Jesús ^a   Bertoncini, Carlos W ^a,e   Estébanez Perpiñá, Eva ^b   McEwan, Iain J ^c   Riera, Antoni ^a,b   Salvatella, Xavier ^a,d  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^e Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION FUNCTION 1 PROTEIN; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; CYTOTOXIC AGENT; EPI 001; GENERAL TRANSCRIPTION FACTOR; TRANSCRIPTION ACTIVATION UNIT 5 PROTEIN; UNCLASSIFIED DRUG; BENZHYDRYL DERIVATIVE; CHLOROHYDRIN DERIVATIVE;

ANIMAL CELL; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CLINICAL FEATURE; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE CELL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; TRANSACTIVATION; TRANSCRIPTION INITIATION; METABOLISM; ORCHIECTOMY; PATHOLOGY; PROSTATIC NEOPLASMS;

BENZHYDRYL COMPOUNDS; CHLOROHYDRINS; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTIONAL ACTIVATION;

EID: 84987892499     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.6b00182     Document Type: Article

References (39)

1. Gelmann, E. P. (2002) Molecular Biology of the Androgen Receptor J. Clin. Oncol. 20, 3001-3015 10.1200/JCO.2002.10.018
2. Akaza, H., Hinotsu, S., Usami, M., Arai, Y., Kanetake, H., Naito, S., and Hirao, Y. (2009) Combined androgen blockade with bicalutamide for advanced prostate cancer Cancer 115, 3437-3445 10.1002/cncr.24395
3. Harris, W. P., Mostaghel, E. A., Nelson, P. S., and Montgomery, B. (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion Nat. Clin. Pract. Urol. 6, 76-85 10.1038/ncpuro1296
4. Karantanos, T., Corn, P. G., and Thompson, T. C. (2013) Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches Oncogene 32, 5501-5511 10.1038/onc.2013.206
5. Reid, J., Kelly, S. M., Watt, K., Price, N. C., and McEwan, I. J. (2002) Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation. Influence of structure-stabilizing solutes and protein-protein interactions J. Biol. Chem. 277, 20079-20086 10.1074/jbc.M201003200
6. Lavery, D. N. and McEwan, I. J. (2008) Structural characterization of the native NH2-terminal transactivation domain of the human androgen receptor: a collapsed disordered conformation underlies structural plasticity and protein-induced folding Biochemistry 47, 3360-3369 10.1021/bi702221e
7. Quayle, S. N., Mawji, N. R., Wang, J., and Sadar, M. D. (2007) Androgen receptor decoy molecules block the growth of prostate cancer Proc. Natl. Acad. Sci. U. S. A. 104, 1331-1336 10.1073/pnas.0606718104
8. Lamberto, G. R., Torres-Monserrat, V., Bertoncini, C. W., Salvatella, X., Zweckstetter, M., Griesinger, C., and Fernandez, C. O. (2011) Toward the discovery of effective polycyclic inhibitors of alpha-synuclein amyloid assembly J. Biol. Chem. 286, 32036-32044 10.1074/jbc.M111.242958
9. Krishnan, N., Koveal, D., Miller, D. H., Xue, B., Akshinthala, S. D., Kragelj, J., Jensen, M. R., Gauss, C.-M., Page, R., Blackledge, M., Muthuswamy, S. K., Peti, W., and Tonks, N. K. (2014) Targeting the disordered C terminus of PTP1B with an allosteric inhibitor Nat. Chem. Biol. 10, 558-566 10.1038/nchembio.1528
10. Metallo, S. J. (2010) Intrinsically disordered proteins are potential drug targets Curr. Opin. Chem. Biol. 14, 481-488 10.1016/j.cbpa.2010.06.169
11. Heller, G. T., Sormanni, P., and Vendruscolo, M. (2015) Targeting disordered proteins with small molecules using entropy Trends Biochem. Sci. 40, 491-496 10.1016/j.tibs.2015.07.004
12. Andersen, R. J., Mawji, N. R., Wang, J., Wang, G., Haile, S., Myung, J.-K., Watt, K., Tam, T., Yang, Y. C., Bañuelos, C. A., Williams, D. E., McEwan, I. J., Wang, Y., and Sadar, M. D. (2010) Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor Cancer Cell 17, 535-546 10.1016/j.ccr.2010.04.027
13. Myung, J.-K., Bañuelos, C. A., Fernandez, J. G., Mawji, N. R., Wang, J., Tien, A. H., Yang, Y. C., Tavakoli, I., Haile, S., Watt, K., McEwan, I. J., Plymate, S., Andersen, R. J., and Sadar, M. D. (2013) An androgen receptor N-terminal domain antagonist for treating prostate cancer J. Clin. Invest. 123, 2948-2960 10.1172/JCI66398
14. Neidhardt, F. C., Bloch, P. L., and Smith, D. F. (1974) Culture medium for enterobacteria J. Bacteriol. 119, 736-747
15. McEwan, I. J. (2012) Intrinsic disorder in the androgen receptor: identification, characterisation and drugability Mol. BioSyst. 8, 82-90 10.1039/C1MB05249G
16. Dunker, A. K., Lawson, J. D., Brown, C. J., Williams, R. M., Romero, P., Oh, J. S., Oldfield, C. J., Campen, A. M., Ratliff, C. M., Hipps, K. W., Ausio, J., Nissen, M. S., Reeves, R., Kang, C., Kissinger, C. R., Bailey, R. W., Griswold, M. D., Chiu, W., Garner, E. C., and Obradovic, Z. (2001) Intrinsically disordered protein J. Mol. Graphics Modell. 19, 26-59 10.1016/S1093-3263(00)00138-8
17. Mohan, A., Oldfield, C. J., Radivojac, P., Vacic, V., Cortese, M. S., Dunker, A. K., and Uversky, V. N. (2006) Analysis of molecular recognition features (MoRFs) J. Mol. Biol. 362, 1043-1059 10.1016/j.jmb.2006.07.087
18. Jenster, G., van der Korput, H. A. G. M., Trapman, J., and Brinkmann, A. O. (1995) Identification of two transcription activation units in the N-terminal domain of the human androgen receptor J. Biol. Chem. 270, 7341-7346 10.1074/jbc.270.13.7341
19. Callewaert, L., Van Tilborgh, N., and Claessens, F. (2006) Interplay between two hormone-independent activation domains in the androgen receptor Cancer Res. 66, 543-553 10.1158/0008-5472.CAN-05-2389
20. Dehm, S. M., Regan, K. M., Schmidt, L. J., and Tindall, D. J. (2007) Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells Cancer Res. 67, 10067-10077 10.1158/0008-5472.CAN-07-1267
21. Metzger, E., Müller, J. M., Ferrari, S., Buettner, R., and Schüle, R. (2003) A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer EMBO J. 22, 270-280 10.1093/emboj/cdg023
22. Kumar, R., Betney, R., Li, J., Thompson, E. B., and McEwan, I. J. (2004) Induced alpha-helix structure in AF1 of the androgen receptor upon binding transcription factor TFIIF Biochemistry 43, 3008-3013 10.1021/bi035934p
23. Tamiola, K., Acar, B., and Mulder, F. A. A. (2010) Sequence-specific random coil chemical shifts of intrinsically disordered proteins J. Am. Chem. Soc. 132, 18000-18003 10.1021/ja105656t
24. Marsh, J. A., Singh, V. K., Jia, Z., and Forman-Kay, J. D. (2006) Sensitivity of secondary structure propensities to sequence differences between alpha- and gamma-synuclein: implications for fibrillation Protein Sci. 15, 2795-2804 10.1110/ps.062465306
25. Klein-Seetharaman, J., Oikawa, M., Grimshaw, S. B., Wirmer, J., Duchardt, E., Ueda, T., Imoto, T., Smith, L. J., Dobson, C. M., and Schwalbe, H. (2002) Long-range interactions within a nonnative protein Science 295, 1719-1722 10.1126/science.1067680
26. Romero, P., Obradovic, Z., Li, X., Garner, E. C., Brown, C. J., and Dunker, A. K. (2001) Sequence complexity of disordered protein Proteins: Struct., Funct., Genet. 42, 38-48 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3
27. Zhu, P., Baek, S. H., Bourk, E. M., Ohgi, K. A., Garcia-Bassets, I., Sanjo, H., Akira, S., Kotol, P. F., Glass, C. K., Rosenfeld, M. G., and Rose, D. W. (2006) Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway Cell 124, 615-629 10.1016/j.cell.2005.12.032
28. Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M., Yang, R., Escara-Wilke, J., Wilder-Romans, K., Dhanireddy, S., Engelke, C., Iyer, M. K., Jing, X., Wu, Y.-M., Cao, X., Qin, Z. S., Wang, S., Feng, F. Y., and Chinnaiyan, A. M. (2014) Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer Nature 510, 278-282 10.1038/nature13229
29. He, B., Bai, S., Hnat, A. T., Kalman, R. I., Minges, J. T., Patterson, C., and Wilson, E. M. (2004) An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP) J. Biol. Chem. 279, 30643-30653 10.1074/jbc.M403117200
30. Migliaccio, A., Castoria, G., Giovannelli, P., and Auricchio, F. (2010) Cross talk between epidermal growth factor (EGF) receptor and extra nuclear steroid receptors in cell lines Mol. Cell. Endocrinol. 327, 19-24 10.1016/j.mce.2010.06.014
31. Gioeli, D., Ficarro, S. B., Kwiek, J. J., Aaronson, D., Hancock, M., Catling, A. D., White, F. M., Christian, R. E., Settlage, R. E., Shabanowitz, J., Hunt, D. F., and Weber, M. J. (2002) Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites J. Biol. Chem. 277, 29304-29314 10.1074/jbc.M204131200
32. Adzhubei, A. A., Sternberg, M. J. E., and Makarov, A. A. (2013) Polyproline-II helix in proteins: structure and function J. Mol. Biol. 425, 2100-2132 10.1016/j.jmb.2013.03.018
33. He, B., Kemppainen, J. A., and Wilson, E. M. (2000) FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor J. Biol. Chem. 275, 22986-22994 10.1074/jbc.M002807200
34. Hur, E., Pfaff, S. J., Payne, E. S., Grøn, H., Buehrer, B. M., and Fletterick, R. J. (2004) Recognition and accommodation at the androgen receptor coactivator binding interface PLoS Biol. 2, E274 10.1371/journal.pbio.0020274
35. Lagarde, W. H., Blackwelder, A. J., Minges, J. T., Hnat, A. T., French, F. S., and Wilson, E. M. (2012) Androgen receptor exon 1 mutation causes androgen insensitivity by creating phosphorylation site and inhibiting melanoma antigen-A11 activation of NH2- and carboxyl-terminal interaction-dependent transactivation J. Biol. Chem. 287, 10905-10915 10.1074/jbc.M111.336081
36. Muñoz, V. and Serrano, L. (1994) Elucidating the folding problem of helical peptides using empirical parameters Nat. Struct. Biol. 1, 399-409 10.1038/nsb0694-399
37. Bruun, S. W., Iešmantavičius, V., Danielsson, J., and Poulsen, F. M. (2010) Cooperative formation of native-like tertiary contacts in the ensemble of unfolded states of a four-helix protein Proc. Natl. Acad. Sci. U. S. A. 107, 13306-13311 10.1073/pnas.1003004107
38. Fenwick, R. B., Esteban-Martín, S., and Salvatella, X. (2011) Understanding biomolecular motion, recognition, and allostery by use of conformational ensembles Eur. Biophys. J. 40, 1339-1355 10.1007/s00249-011-0754-8
39. Shaffer, P. L., Jivan, A., Dollins, D. E., Claessens, F., and Gewirth, D. T. (2004) Structural basis of androgen receptor binding to selective androgen response elements Proc. Natl. Acad. Sci. U. S. A. 101, 4758-4763 10.1073/pnas.0401123101